Program
CME/CPD Points
RANZCP CPD Program
Time psychiatrists spend participating in this educational activity can be claimed in the RANZCP CPD Program. As the CPD Program is hours-based, you will need to record the length of time you participate and retain some evidence of your attendance, such as registration confirmation, tax invoice for registration, or program from the event.
APS (Australian Psychological Society)
RACGP (Royal Australian College of General Practitioners)
This activity has been approved by the RACGP QA&CPD Program and has been allocated 2 points per hour (Category 2). Total - 27 points.
Royal College of Nursing, Australia
The number of points applicable to the conference is 13.5.
The Australian College of Mental Health Nurses Inc
ACMHN Endorsement 18 CPE points
Speakers
Greg Barns
Greg Barns is a barrister, writer and commentator. He practices in the area of human rights and criminal defence in Melbourne and Hobart. Greg is also legal adviser to Prison Action Reform and is a Director of the Australian Lawyers Alliance. He is a former senior political adviser to a number of Liberal Party premiers and federal government ministers and ran the 1999 Republic campaign for the Australian Republican Movement. From 2000-02 Greg was Chair of the ARM. He left the Liberal Party in 2002 after it disendorsed him for his support for asylum seekers and along with Howard Glenn worked for refugee advocacy group A Just Australia. Along with Howard Glenn he has formed national human rights organization Rights Australia. Greg is the author of three books on Australian politics and writes regularly for the Hobart Mercury, Crikey, the South China Morning Post and Online Opinion. He also a non-executive director of four companies involved in the resources sector, and was this year appointed an Ambassador for Beyond Blue.
Prof Michael Berk
Professor Michael Berk is currently appointed to the Chair of Psychiatry for Barwon Health and The Geelong Clinic at The University of Melbourne. He also is an Honorary Professorial Research fellow at the Mental Health Research Institute, and leads the first episode bipolar program at Orygen Youth Health. He has published over 250 papers on a range of topics with his research interests focusing on mood and psychotic disorders, particularly bipolar disorder and depression. He is Chairman of the International Society of Bipolar Disorders, and Vice Chairman of the Australasian Society of Bipolar Disorders. He is a committee member of both the Collegium Internationale Psychopharmacologicum and World Federation of Societies of Biological Psychiatry is a member of a number of international advisory boards. He was the founding editor of The Journal of Depression and Anxiety, has served as guest editor or is on the editorial board of 12 other journals as well as being a reviewer of 30 journals.
Professor K.N. Roy Chengappa
K.N. Roy Chengappa, MD, is a Professor of Psychiatry in the Department of Psychiatry at the University Of Pittsburgh School Of Medicine and the Western Psychiatric Institute and Clinic, and is Chief, Services for Research and Recovery in Serious Mental Illness at Western Psychiatric Institute and Clinic, in Pittsburgh, Pennsylvania. Dr. Chengappa received his medical degree from Kasturba Medical College, Manipal of the University of Mysore in India. His psychiatric training took place worldwide, beginning at the National Institute of Mental Health and Neuroscience in Bangalore, India, then at the University of Edinburgh in Scotland, and finally at Dalhousie University in Halifax, Nova Scotia, Canada. He completed a 2-year US National Institute of Mental Health-sponsored fellowship at Western Psychiatric Institute and Clinic in Pittsburgh, before joining the faculty there. Dr Chengappa has published several articles in peer-reviewed journals and is Co-Editor in Chief of the journal Bipolar Disorders. For 20 years, he has conducted clinical trials of second-generation antipsychotic and anticonvulsant agents in subjects with schizophrenia or bipolar disorder. He is currently conducting trials of cognition enhancing drugs for persons with severe mental illness. He has direct patient care responsibilities. He is also involved in the mentoring of psychiatric residents and medical students.
Dr Francesc Colom
Doctor Cum Laude in Psychology, Master of Social Psychiatry at the University of Barcelona, Master in Affective Neuroscience at the Maastricht University, The Netherlands and Post-graduate in Psychopharmacology and Psychobiology from the University of Barcelona. Dr Colom is currently the Head of the Psychoeducation and Psychological Treatments Area at the Barcelona Bipolar Disorders Program (IDIBAPS- Hospital Clinic University of Barcelona), under the sponsorship of the Centre for Research in Health Network Mental (CIBERSAM) and the Spanish Ministry of Science and Innovation. Dr. Colom has conducted and published the largest study on the efficacy of psycho-education in bipolar disorders. He has published over 90 articles in international journals, focusing on the clinical understanding of bipolar patients, pharmacotherapy, psychological interventions, co-morbidity, suicide and improving compliance. He has also published a total of 12 books on affective disorders, both for professionals and consumers. His "Manual of psycho-education for bipolar disorders" has been translated into four languages. Dr Colom is part of the Nomenclature Committee of the International Society for Bipolar Disorders, chairs the ISBD Website Education Committee for the same society and is member of the Scientific Advisory Pannel of the ECNP. Dr. Colom is Visiting Professor of Psychiatry at the University of Caglari (Italy), honorary professor of the Institute of Psychiatry, King's College of London (UK) and professor of various university courses for Masters and Post-graduate courses, and reviewer and editorial board member of several international scientific journals. In June 2007 he was awarded the "Mogens Schou" Award, the highest international distinction in research on bipolar disorders.
Joseph F. Goldberg
Joseph Goldberg MD is Associate Clinical Professor of Psychiatry at the Mount Sinai School of Medicine and Director of the Affective Disorders Research Program at Silver Hill Hospital, New Canaan, CT. He attended college at the University of Chicago, then earned an MS in neuroscience from the University of Illinois and an MD degree from Northwestern University School of Medicine. He completed his internship, residency in psychiatry, and research fellowship in the psychopharmacology of mood disorders at the Payne Whitney Clinic of New York Presbyterian Hospital, where he subsequently served on the faculty and was director of the Bipolar Disorders Research Clinic, and was site principal investigator there for the NIMH Systematic Treatment Enhancement Program for Bipolar Disorders (STEP-BD). Dr. Goldberg received two NARSAD Young Investigator Awards and a Career Development Award from the NIMH, as well as research funding from the Theodore and Vada Stanley Foundation and the American Society for Suicide Prevention. He is the author of over 140 peer-reviewed scientific publications as well as two edited texts on bipolar disorder published by the American Psychiatric Press, most recently, "Cognitive Dysfunction in Bipolar Disorder: A Guide for Clinicians."
Prof Gordon Johnson
Gordon Johnson is Emeritus Professor of Psychological Medicine at the University of Sydney and Director Mood Disorders Unit Northside Clinic. He graduated MBBS from University of Queensland in 1959. He obtained Post Graduate training Psychiatry in the UK and in psychopharmacology research in the USA. Gordon is a Foundation Member and later Fellow of the Royal Australian and New Zealand College of Psychiatrists and the Royal College of Psychiatrists. He was visiting Professor at the University of Malaysia in 1982 and at the University of Pittsburgh in 1992. He was a recipient of the Organon Prize for research in 1982. He has published extensively in national and international journals and is on the Executive Editorial Board of the Journal of Bipolar Disorders and Comprehension Psychiatry. He is a member of the Australian Drug Evaluation Committee and past member of the Pharmaceutical Benefits Committee.